Tocagen Inc (NASDAQ:TOCA) Given Average Rating of “Buy” by Analysts

Share on StockTwits

Shares of Tocagen Inc (NASDAQ:TOCA) have earned an average rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $16.00.

A number of research analysts recently issued reports on TOCA shares. HC Wainwright reissued a “buy” rating on shares of Tocagen in a research note on Friday, August 9th. Leerink Swann set a $5.00 price objective on shares of Tocagen and gave the company a “hold” rating in a research note on Wednesday, May 22nd. Chardan Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Tocagen in a research note on Wednesday, May 22nd. ValuEngine raised shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research cut shares of Tocagen from a “buy” rating to a “hold” rating in a research note on Friday.

In related news, Director Faheem Hasnain bought 43,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The shares were purchased at an average price of $4.66 per share, with a total value of $200,380.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have acquired 53,000 shares of company stock worth $244,880. Insiders own 10.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in shares of Tocagen by 9.4% during the first quarter. Rhumbline Advisers now owns 25,491 shares of the company’s stock worth $277,000 after buying an additional 2,188 shares during the last quarter. Stifel Financial Corp grew its stake in shares of Tocagen by 34.0% in the fourth quarter. Stifel Financial Corp now owns 26,392 shares of the company’s stock worth $215,000 after purchasing an additional 6,698 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Tocagen in the fourth quarter worth $295,000. Bank of New York Mellon Corp grew its stake in shares of Tocagen by 7.7% in the fourth quarter. Bank of New York Mellon Corp now owns 56,938 shares of the company’s stock worth $468,000 after purchasing an additional 4,093 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in shares of Tocagen in the first quarter worth $1,304,000. 35.06% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:TOCA traded up $0.16 during mid-day trading on Friday, reaching $4.52. The stock had a trading volume of 263,000 shares, compared to its average volume of 174,154. The stock has a 50-day simple moving average of $5.51 and a two-hundred day simple moving average of $8.18. The stock has a market capitalization of $102.76 million, a PE ratio of -1.85 and a beta of 3.90. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.21 and a quick ratio of 5.05. Tocagen has a 12 month low of $4.12 and a 12 month high of $15.80.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.04. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.50 million. Tocagen had a negative net margin of 300.42% and a negative return on equity of 115.81%. Equities analysts expect that Tocagen will post -2.67 EPS for the current year.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Featured Story: How interest rates affect municipal bond prices

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VANGUARD SCOTTS/VANGUARD RUSSELL 20  Shares Sold by Private Advisor Group LLC
VANGUARD SCOTTS/VANGUARD RUSSELL 20 Shares Sold by Private Advisor Group LLC
Private Advisor Group LLC Increases Stock Holdings in Invesco BulletShares 2019 Corporate Bond ETF
Private Advisor Group LLC Increases Stock Holdings in Invesco BulletShares 2019 Corporate Bond ETF
Private Advisor Group LLC Cuts Holdings in salesforce.com, inc.
Private Advisor Group LLC Cuts Holdings in salesforce.com, inc.
Private Advisor Group LLC Sells 25,360 Shares of PPL Corp
Private Advisor Group LLC Sells 25,360 Shares of PPL Corp
Invesco DWA Tactical Sector Rotation ETF  Shares Sold by Private Advisor Group LLC
Invesco DWA Tactical Sector Rotation ETF Shares Sold by Private Advisor Group LLC
PVG Asset Management Corp Sells 225,220 Shares of Ares Capital Co.
PVG Asset Management Corp Sells 225,220 Shares of Ares Capital Co.


 
© 2006-2019 Zolmax.